Clinical trial • Phase III|Phase IV • Respiratory

ROCURONIUM BROMIDE for Respiratory distress

Phase III|Phase IV trial of ROCURONIUM BROMIDE for Respiratory distress.

Overview

Trial Therapeutic Area
Respiratory
Trial Disease
Respiratory distress
Trial Stage
Phase III|Phase IV
Drug Modality
Small molecule

Key dates

Initial CTIS Submission Date
26-07-2024
First CTIS Authorization Date
12-09-2024

Trial design

Randomised, open-label, experimental group: combined strategy integrating rocuronium (rocuronium bromide), bag face-mask ventilation before intubation and gum elastic bougie (geb). control group: usual tracheal intubation process. no specific doses or schedules for the comparator arms are specified in the available record. Phase III|Phase IV trial in France.

Randomised
Yes
Open Label
Yes
Comparator
Experimental group: Combined strategy integrating rocuronium (rocuronium bromide), bag face-mask ventilation before intubation and gum elastic bougie (GEB). Control group: Usual tracheal intubation process. No specific doses or schedules for the comparator arms are specified in the available record.
Target Sample Size
1500
Trial Duration For Participant
28

Eligibility

Recruits 1500 Patients under specific protection measures (pregnant, parturient or nursing women; patients under judicial protection, guardianship/curatorship; deprived of liberty) are explicitly listed as excluded. The trial population is adults (≥18 years). Subject information and informed consent forms for adults are provided (documents: 'L1_SIS and ICF_adults' and 'L1_SIS and ICF_adults_TC'); no assent/minor consent procedures are described because minors are excluded..

Pregnancy Exclusion
Patient under specific protection measures: pregnant, parturient or nursing women ; legal protection or deprived of liberty : patient under judicial protection, patient under guardianship/curatorship
Vulnerable Population
Patients under specific protection measures (pregnant, parturient or nursing women; patients under judicial protection, guardianship/curatorship; deprived of liberty) are explicitly listed as excluded. The trial population is adults (≥18 years). Subject information and informed consent forms for adults are provided (documents: 'L1_SIS and ICF_adults' and 'L1_SIS and ICF_adults_TC'); no assent/minor consent procedures are described because minors are excluded.

Inclusion criteria

  • {"criterion_text":"- Adult (≥ 18 years) patient presenting with vital distress needing an emergency endotracheal intubation , and treated by the participating SMUR"}
  • {"criterion_text":"- Patient with all conditions (trauma, dyspnea, coma, overdoses, and shock) except those in cardiac arrest"}

Exclusion criteria

  • {"criterion_text":"- Patient presenting of a contraindication to succinylcholine, and/or rocuronium, and/or sugammadex (rocunorium antagonist)"}
  • {"criterion_text":"- Patient who have contraindication to bag face mask ventilation before intubation (ongoing emesis, hematemesis, or hemoptysis)"}
  • {"criterion_text":"- Patient that are not members of a medical aid scheme (beneficiary or main member)"}
  • {"criterion_text":"- Patient under specific protection measures: pregnant, parturient or nursing women ; legal protection or deprived of liberty : patient under judicial protection, patient under guardianship/curatorship"}

Endpoints

Primary endpoints

  • {"endpoint_text":"- proportion of patients with severe intubation-related complications occurring during the first hour after intubation. Severe intubation-related complications are: Cardiac arrest. At least one arterial hypotension episode defined by systolic blood pressure<90 mmHg. At least one hypoxemia episode defined by an occurrence of a new episode of oxygen saturation<90%. Severe cardiac arrhythmia: ventricular tachycardia. Pulmonary aspiration. Esophageal intubation. Unintentional extubation.","definition_or_measurement_approach":"Severe intubation-related complications defined as: Cardiac arrest; ≥1 arterial hypotension episode (systolic BP < 90 mmHg); ≥1 hypoxemia episode (new occurrence of oxygen saturation <90%); severe cardiac arrhythmia (ventricular tachycardia); pulmonary aspiration; esophageal intubation; unintentional extubation. Measured as proportion of patients experiencing these events during the first hour after intubation."}

Secondary endpoints

  • {"endpoint_text":"- Difficulty of the intubation process: Intubation Difficulty Score: Intubation Difficulty Score > 5 defining difficult intubation.18","definition_or_measurement_approach":"Proportion of patients with Intubation Difficulty Score (IDS) > 5 defining difficult intubation."}
  • {"endpoint_text":"- Difficulty of the intubation process: Intubation conditions assessed by the Copenhagen score19: Poor conditions/Good conditions/Excellent conditions","definition_or_measurement_approach":"Intubation conditions assessed using the Copenhagen score categorized as Poor / Good / Excellent."}
  • {"endpoint_text":"- Difficulty of the intubation process: Proportion of patients intubated by alternative techniques (stylet, gum elastic bougie, Intubating Laryngeal Mask Airway (ILMA) [e.g., Fastrach], or cricothyrotomy)","definition_or_measurement_approach":"Proportion of patients requiring alternative intubation techniques (stylet, gum elastic bougie, ILMA, or cricothyrotomy)."}
  • {"endpoint_text":"- Difficulty of the intubation process: Mean number of intubation attempts","definition_or_measurement_approach":"Mean (average) number of intubation attempts per patient."}
  • {"endpoint_text":"- Difficulty of the intubation process: Mean number of intubation failures under direct laryngoscopy","definition_or_measurement_approach":"Mean number of intubation failures when using direct laryngoscopy."}
  • {"endpoint_text":"- Out-of hospital care: Mean time of out-of-hospital care (in minutes), defined from time of SMUR arrival on scene to time of hospitalization","definition_or_measurement_approach":"Mean duration (minutes) of out-of-hospital care measured from SMUR arrival on scene to hospital admission."}
  • {"endpoint_text":"- Out-of hospital care: Mean total amount of sedative drugs used after intubation","definition_or_measurement_approach":"Mean total quantity of sedative drugs administered after intubation (specific measurement units not provided)."}
  • {"endpoint_text":"- Out-of hospital care: Mean total amount of vasopressors used after intubation","definition_or_measurement_approach":"Mean total quantity of vasopressors administered after intubation (specific measurement units not provided)."}
  • {"endpoint_text":"- Out-of hospital care: Out-of-hospital mortality, defined as the proportion of patients who died during the out-of-hospital time","definition_or_measurement_approach":"Proportion of patients who died during the out-of-hospital time."}
  • {"endpoint_text":"- Mortality at 28 days: The follow-up of patients stopping at hospital admission, the vital status of the patient will be retrieved using the open-access French Register of deceased persons (\"Fichier des personnes décédées\") maintained by INSEE (website: https://deces.matchid.io/search)","definition_or_measurement_approach":"Vital status at 28 days obtained via the French Register of deceased persons (INSEE) to determine 28-day mortality."}

Recruitment

Planned Sample Size
1500
Recruitment Window Months
44
Consent Approach
Informed consent handled using adult subject information and informed consent forms (documents listed: 'L1_SIS and ICF_adults' and 'L1_SIS and ICF_adults_TC'). Participants are adults (≥18) who provide consent; no assent or minor-specific consent procedures are described in the available records.

Methods

  • Enrolment occurs via participating SMUR (emergency medical service) teams during out-of-hospital emergency tracheal intubations in France; patients are identified and enrolled at the point of care by treating SMUR clinicians.

Geography

Total Number Of Sites
19
Total Number Of Participants
1500

France

Earliest CTIS Part Ii Submission Date
31-07-2024
Latest Decision Or Authorization Date
03-09-2025
Processing Time Days
399
Number Of Sites
19
Number Of Participants
1500

Sites

Site Name
Centre Hospitalier Universitaire Grenoble Alpes
Department Name
SMUR Urgences adultes
Principal Investigator Name
Guillaume DEBATY
Principal Investigator Email
gdebaty@chu-grenoble.fr
Contact Person Name
Guillaume DEBATY
Contact Person Email
gdebaty@chu-grenoble.fr
Site Name
Hopital NOVO
Department Name
SMUR Urgences adultes - CH René Dubois Pontoise
Principal Investigator Name
Agnès RICARD-HIBON
Principal Investigator Email
agnes.ricard-hibon@ght-novo.fr
Contact Person Name
Agnès RICARD-HIBON
Contact Person Email
agnes.ricard-hibon@ght-novo.fr
Site Name
Groupement Hospitalier Eaubonne Montmorency Simone Veil
Department Name
SMUR Urgences adultes
Principal Investigator Name
Laure GUILLOUX
Principal Investigator Email
laureguilloux@hotmail.fr
Contact Person Name
Laure GUILLOUX
Contact Person Email
laureguilloux@hotmail.fr
Site Name
Centre Hospitalier Universitaire De La Reunion
Department Name
SMUR Urgences adultes
Principal Investigator Name
Adrien MARTEAU
Principal Investigator Email
adrien.marteau@chu-reunion.fr
Contact Person Name
Adrien MARTEAU
Contact Person Email
adrien.marteau@chu-reunion.fr
Site Name
Assistance Publique Hopitaux De Paris (Creteil)
Department Name
SMUR Urgences adultes
Principal Investigator Name
Charlotte CHOLLET-XEMARD
Principal Investigator Email
charlotte.chollet@aphp.fr
Contact Person Name
Charlotte CHOLLET-XEMARD
Contact Person Email
charlotte.chollet@aphp.fr
Site Name
Assistance Publique Hopitaux De Paris (Garches)
Department Name
SMUR Urgences adultes
Principal Investigator Name
Armelle SEVERIN
Principal Investigator Email
armelle.severin@aphp.fr
Contact Person Name
Armelle SEVERIN
Contact Person Email
armelle.severin@aphp.fr
Site Name
Assistance Publique Hopitaux De Paris (2 Rue Ambroise Pare)
Department Name
SMUR Urgences adultes
Principal Investigator Name
Xavier Dominique EYER
Principal Investigator Email
xavier.eyer@aphp.fr
Contact Person Name
Xavier Dominique EYER
Contact Person Email
xavier.eyer@aphp.fr
Site Name
Assistance Publique Hopitaux De Paris (43 Boulevard De L Hopital)
Department Name
SMUR Urgences adultes
Principal Investigator Name
Patrick ECOLLAN
Principal Investigator Email
patrick.ecollan@aphp.fr
Contact Person Name
Patrick ECOLLAN
Contact Person Email
patrick.ecollan@aphp.fr
Site Name
Centre Hospitalier Universitaire De Bordeaux
Department Name
SMUR Urgences adultes
Principal Investigator Name
Xavier COMBES
Principal Investigator Email
xavier.combes@chu-bordeaux.fr
Contact Person Name
Xavier COMBES
Contact Person Email
xavier.combes@chu-bordeaux.fr
Site Name
Hopital NOVO (Pontoise site)
Department Name
SMUR Urgences adultes - Site Beaumont
Principal Investigator Name
Agnès RICARD-HIBON
Principal Investigator Email
agnes.ricard-hibon@ght-novo.fr
Contact Person Name
Agnès RICARD-HIBON
Contact Person Email
agnes.ricard-hibon@ght-novo.fr
Site Name
Assistance Publique Hopitaux De Paris (Bobigny)
Department Name
SMUR Urgences adultes
Principal Investigator Name
Frédéric LAPOSTOLLE
Principal Investigator Email
frederic.lapostolle@aphp.fr
Contact Person Name
Frédéric LAPOSTOLLE
Contact Person Email
frederic.lapostolle@aphp.fr
Site Name
Centre Hospitalier Universitaire D'Angers
Department Name
SMUR Urgences adultes
Principal Investigator Name
Dominique SAVARY
Principal Investigator Email
dominique.savary@chu-angers.fr
Contact Person Name
Dominique SAVARY
Contact Person Email
dominique.savary@chu-angers.fr
Site Name
Centre Hospitalier Universitaire De Poitiers
Department Name
SMUR Urgences adultes
Principal Investigator Name
Nicolas MARJANOVIC
Principal Investigator Email
patrick.ecollan@aphp.fr
Contact Person Name
Nicolas MARJANOVIC
Contact Person Email
patrick.ecollan@aphp.fr
Site Name
Assistance Publique Hopitaux De Paris (149 Rue De Sevres)
Department Name
SMUR Urgences adultes
Principal Investigator Name
Benoît VIVIEN
Principal Investigator Email
benoit.vivien@aphp.fr
Contact Person Name
Benoît VIVIEN
Contact Person Email
benoit.vivien@aphp.fr
Site Name
Centre Hospitalier Universitaire De Montpellier
Department Name
SMUR Urgences adultes
Principal Investigator Name
Xavier BOBBIA
Principal Investigator Email
xavier.bobbia@chu-montpellier.fr
Contact Person Name
Xavier BOBBIA
Site Name
Hospices Civils De Lyon
Department Name
SMUR Urgences adultes
Principal Investigator Name
Marine PAUPE
Principal Investigator Email
marine.paupe@chu-lyon.fr
Contact Person Name
Marine PAUPE
Contact Person Email
marine.paupe@chu-lyon.fr
Site Name
Centre Hospitalier Universitaire De Toulouse
Department Name
SMUR Urgences adultes
Principal Investigator Name
Bertrand GUIHARD
Principal Investigator Email
guihard.b@chu-toulouse.fr
Contact Person Name
Bertrand GUIHARD
Contact Person Email
guihard.b@chu-toulouse.fr
Site Name
Groupe Hospitalier Du Sud Ile De France
Department Name
SMUR Urgences adultes
Principal Investigator Name
Yousra GUETARI
Principal Investigator Email
yousra.guetari@ghsif.fr
Contact Person Name
Yousra GUETARI
Contact Person Email
yousra.guetari@ghsif.fr
Site Name
Centre Hospitalier Universitaire De Nantes
Department Name
SMUR Urgences adultes
Principal Investigator Name
Quentin LE BASTARD
Principal Investigator Email
quentin.lebastard@chu-nantes.fr
Contact Person Name
Quentin LE BASTARD

Sponsor

Primary sponsor

Full Name
Centre Hospitalier Universitaire De Bordeaux
Organisation Type
Hospital/Clinic/Other health care facility
Country Of Registered Address
France

Investigational products

Investigational Product Name
ROCURONIUM VIATRIS 10 mg/mL, solution injectable/pour perfusion
Active Substance
ROCURONIUM BROMIDE
Modality
Small molecule
Routes Of Administration
INTRAVENOUS USE
Route
INTRAVENOUS USE
Authorisation Status
Authorised
Maximum Dose
10 mg/ml
Investigational Product Name
CELOCURINE 50 mg/ml, solution injectable
Active Substance
SUXAMETHONIUM CHLORIDE
Modality
Small molecule
Routes Of Administration
INTRAVENOUS USE
Route
INTRAVENOUS USE
Authorisation Status
Authorised
Maximum Dose
1 mg/kg
Investigational Product Name
SUGAMMADEX JUTA PHARMA 100 mg/mL, solution injectable
Active Substance
SUGAMMADEX
Modality
Small molecule
Routes Of Administration
INTRAVENOUS USE
Route
INTRAVENOUS USE
Authorisation Status
Authorised
Maximum Dose
100 mg/ml
Combination Treatment
Yes

Related trials

Other published trials that may interest you.